CIS Pharma was awarded with the 2011 European Frost & Sullivan Technology Innovation Award for its unique Cellophil® Smart Polymer technology.
“Cellophil® is a novel biomaterial based on bi-functional amino-acids that exhibits superior biocompatibility, resolving issues with conventional medical-grade polymers for bio-medical use”, remarks Frost & Sullivan research analyst Arpita Mukherjee. „The polymer can be loaded with drugs for target-specific release, improving the quality of patient care and addressing unmet medical needs. With its intelligent functionally, Cellophil® is finding strong prospects in various bio-medical applications.”
„The most noticeable factor is the control over chemical and physical properties. Drugs delivered site- and target-specific by Cellophil® reduce or eliminate the adverse effect of the drug on other body parts“, explains Mukherjee. „With such intelligent functionality, Cellophil® polymer technology opens a wide range of applications for drug delivery, bio-medical implants and replacements.“
Based on different Cellophil® Smart Polymers, CIS Pharma is developing indication-specific bio-medical products that include drug delivery systems for Ophthalmology and Oncology as well as products for reconstructive indications such as bone-replacement and new materials for contact lenses. „In the field of ophthalmology, Cellophil® will change the way allergies, dry eye, uveitis and age-related macular degeneration are treated“, says Mukherjee. „Another application is to create a hydrophilic property on silicon-hydrogel contact lenses for increased contact lens wearing comfort.“